Kura Oncology C.S.O. Francis Burrows Exercises Options, Sells Shares

What Happened

• Francis Burrows, Chief Scientific Officer of Kura Oncology (KURA), exercised stock options and sold shares on September 24, 2026. He exercised a total of 60,000 option shares: 30,000 shares were acquired at $6.15 per share (total cost $184,500) and 30,000 shares were treated as surrendered/disposed as part of the exercise. Separately, Burrows sold 20,726 shares in an open-market transaction at a weighted average price of $10.83, receiving $224,514.

Key Details

• Transaction date: 2026-09-24; Form 4 filed 2026-09-25 (timely).
• Option exercise: 60,000 options exercised (30,000 acquired @ $6.15; 30,000 disposed @ $0 as part of the exercise).
• Open-market sale: 20,726 shares sold for a weighted average price of $10.82–$10.85 (reported weighted avg $10.83) for proceeds of $224,514.
• Shares owned after transaction: not specified in this filing.
• Notable footnotes:
  • F1: Cashless exercise and sale of a portion of a stock option to cover estimated payroll tax liability.
  • F3: Sale executed in multiple trades at prices ranging $10.82–$10.85; weighted average reported.
  • F4: The option exercised is fully vested.
  • F2: Filing notes 629 shares were acquired earlier (May 17, 2026) under the issuer’s Employee Stock Purchase Plan.
• Insider status: Executive officer (not a 10% owner).

Context

• This was a cashless option exercise: some option shares were surrendered/sold to cover tax and exercise obligations while a net number of shares (30,000) were received. The separate open-market sale likely reflects part of that cashless arrangement rather than an independent investment decision. Such exercises and related partial sales are common for tax/liquidity purposes and do not, by themselves, indicate a change in insider sentiment.